National Bank of Greece completes latest round in ongoing share buyback program

Pavlos Mylonas CEO
Pavlos Mylonas CEO
0Comments

National Bank of Greece S.A. has announced the purchase of 384,720 of its own common shares on the Athens Stock Exchange between July 21 and July 28, 2025. The weighted average price for these transactions was €11.9161 per share, resulting in a total cost of €4,584,346.60.

The buyback is part of the first tranche of a program approved by shareholders at the Annual General Meeting held on May 30, 2025. The program also received approval from the Single Supervisory Mechanism (SSM) of the European Central Bank on May 28, 2025.

According to the bank’s statement: “It is noted that in accordance with the resolutions of above-mentioned Annual General Meeting, the Bank intends to proceed with a subsequent cancellation of the above acquired own shares, in accordance with the relevant provisions regarding the time frame for the cancellation of Law 4548/2018.”

During this period, daily purchases ranged from 50,000 to nearly 130,000 shares per day at prices fluctuating between €11.67 and €12.19 per share.

After these transactions, National Bank of Greece S.A. now directly holds a total of 5,807,874 own shares—representing approximately 0.63% of its share capital.

The announcement was made in line with EU Regulation No 596/2014 and Commission Delegated Regulation (EU) 2016/1052 as well as Resolution No 25 from the Stock Markets Steering Committee of the Athens Exchange.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.